Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight. Find out which name…
The portfolio size needed to generate a six-figure passive income swings by nearly $2 million depending on one decision, and getting that decision wrong could leave your monthly check vulnerable to a…
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull…
Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really…
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to…
Most retirees obsess over yield and payout ratios, but neither metric has actually survived a recession, a rate spike, or a global pandemic on your behalf. One number has, and it changes…
Joel South A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb…
When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64…
Retirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn. The three names below cover three distinct roles: a healthcare Dividend King…
Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can…
Retirees chasing a simple $500 monthly check from VYM run straight into a gap between how yields are calculated and how cash actually lands in your account, and the math gets uncomfortable…
Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year…
